Trump, Pfizer announce agreement to lower U.S. drug prices
US President Donald Trump announced an agreement with Pfizer to reduce Medicaid pharmaceutical prices in the White House’s Oval office on September 30, 2025, Washington, DC.
Win McNamee | Getty Images
President Donald Trump announced on Tuesday that he had made an agreement. Pfizer The administration of the US pushes drug prices to associate with cheaper ones abroad to voluntarily sell their medication.
Pfizer agreed to take measures to sell existing drugs to Medicaid patients at the lowest price offered in other developed countries or to reduce US medicine prices, including Trump’s most precious nation price. Pfizer will also guarantee the same “most nationalized” pricing in new drugs for Medicare, Medicaid and commercial payments.
As a part of the agreement, Pfizer has accepted a three -year unpaid time, where the company’s products will not encounter Farmasötik tariffs as long as the drug producer has invested more in US production. The company plans to invest $ 70 billion to reorganizing domestic drug production and research facilities.
After the announcement, Pfizer shares rose by more than 4% on Tuesday.
“Pfizer agreed to provide some of the most popular drugs to our consumers at large discount prices of 50% to 100%.”
Trump added that he was working with other drug producers to secure similar agreements next week and that Pfizer was the first.
“If we don’t make a deal, we’ll describe them,” he said drugs of other companies.
The agreement comes because Trump is faced with the deadline date of Trump to take steps to reduce drug prices, as stated in the letters from the President of the Pfizer and other 16 drug producers. In May, Trump signed an executive order that revives the “most preferred nation” policy, a controversial plan, which aims to connect the prices of some drugs in the United States to those with significant lower abroad.
During the press conference, Pfizer CEO Albert Bourla said that the company also satisfied the fourth of Trump’s letter. Other steps include more difficult price negotiations abroad and adopting models that sell their medicines directly to consumers or businesses.
“There will be clear American patients, there is no doubt.” He said. “They will have a significant impact on their drug purchasing capabilities.” However, “American innovation and American economy” will be “winners” with the agreement, he said.
Pfizer’s Discounted Drugs
Pfizer, according to a statement from the company, priority maintenance treatments and some private branded drugs will offer a large share of up to 50% and 85% discounts, he said.
In a separate statement on Tuesday, Pfizer said that more than 100 million patients were affected by these drugs such as migraine, rheumatoid arthritis, menopause and atopic dermatitis.
The company gave discounted drugs under Trpsprx.gov. DuveeA treatment for certain menopausal symptoms will be offered at a price up to $ 30 on the site, which is 85% discount on the current price.
Patients will also be able to reduce 80% of the prescription ointment Eucrisa, which is used to treat mild to medium eczema, 80% of the feast price. Tovias, a drug for an extremely active bladder, will be offered at a price of $ 42 in Trpsprx.gov, which is 85% discount at the current price.
Pfizer also 60% discount for autoimmune diseases such as Abrilada products, 40% discount for rheumatoid arthritis for Xeljanz and 50% discount of migraine medicine is planning to offer zazvpret, he said.
These drugs do not seem to be important income drivers for Pfizer. The company’s three -month and full -year earning reports include product -specific revenue only for Xeljanz. 349 million dollars worldwide In 2024. Pharmaceutical sales fell from 2023 to 29%, primarily globally, due to lower demand and lower net prices in the USA.
The agreement is preparing for drug producers for Trump’s tariffs planned for pharmaceuticals imported to the country. Trump said in a real social article on Thursday, the US will apply a 100% tariff to the “branded or patented pharmaceutical product” entering the country since October 1.
Trump said the measure will not be valid for companies that build drug production facilities in the USA. He added that the exemption covers the projects that the construction has started, including sites that break the floor or under construction.
In a note on Tuesday, BMO Capital Markets Analyst Evan Seigerman said the agreement is positive for Pfizer’s shares and the wider pharmaceutical sector, because “he adds certainty and takes potus policies out of the drug tariffs.”
“Today’s agreement sets a way for other drug players to follow, allowing headline pricing privileges and the most preferred nation policy or tariffs without a more punishing application.
